Krishnaveni Manubolu | Pharmaceutical Sciences | Research Excellence Award

Published on by Best Paper Awards

Research Excellence Award

KRISHNAVENI MANUBOLU
Narayana Pharmacy College

KRISHNAVENI MANUBOLU
Affiliation Narayana Pharmacy College
Country India
Scopus ID 57222627724
Documents 29
Citations 112
h-index 7
Subject Area Pharmaceutical Sciences
Event Best Paper Awards
ORCID 0000-0002-9401-1768

KRISHNAVENI MANUBOLU is a researcher affiliated with Narayana Pharmacy College, India, whose work in pharmaceutical sciences has contributed to advancing knowledge in drug development, formulation science, and therapeutic evaluation. Her academic contributions are reflected through peer-reviewed publications indexed in international databases, demonstrating consistent scholarly engagement and research productivity [1].

Abstract

This article presents an academic overview of KRISHNAVENI MANUBOLU, highlighting her research achievements, publication record, and contributions to pharmaceutical sciences. The evaluation emphasizes her scholarly productivity, citation metrics, and alignment with criteria for research excellence recognition [1].

Keywords

  • Pharmaceutical Sciences
  • Drug Development
  • Research Impact
  • Academic Publications
  • Scopus Metrics

Introduction

Research excellence awards recognize scholars who demonstrate consistent contributions to scientific advancement. KRISHNAVENI MANUBOLU’s academic profile reflects a commitment to pharmaceutical research, supported by peer-reviewed outputs and citation-based impact indicators [1].

Research Profile

Her research profile includes 29 indexed documents with 112 citations and an h-index of 7, indicating moderate but steady scholarly influence within pharmaceutical sciences. These metrics are commonly used to assess research productivity and citation impact in academic evaluations [1].

Research Contributions

KRISHNAVENI MANUBOLU has contributed to areas such as pharmaceutical formulation, drug delivery systems, and therapeutic studies. Her work supports advancements in healthcare applications and contributes to ongoing research efforts in pharmaceutical sciences [2].

Publications

Her publication record includes articles in peer-reviewed journals indexed in international databases. These publications contribute to the dissemination of pharmaceutical research findings and support academic collaboration and citation growth [2].

Research Impact

The citation count and h-index reflect the measurable influence of her work. These indicators suggest engagement with the research community and the relevance of her studies within the pharmaceutical domain [1].

Award Suitability

Based on her academic output, citation metrics, and subject specialization, KRISHNAVENI MANUBOLU demonstrates eligibility for research excellence recognition. Her contributions align with evaluation criteria commonly applied in academic award assessments.

Conclusion

KRISHNAVENI MANUBOLU’s academic profile reflects consistent research engagement and contribution to pharmaceutical sciences. Her publication record and citation metrics support her recognition within the academic community and justify consideration for research excellence awards.

References

  1. Elsevier. (n.d.). Scopus author details: KRISHNAVENI MANUBOLU, Author ID 57222627724. Scopus.
    https://www.scopus.com/authid/detail.uri?authorId=57222627724

  2. Metal Oxide Nanocatalysts: Eco-friendly Solutions for Catalysis in Green Chemistry.
    https://onlinelibrary.wiley.com/doi/abs/10.1002/9783527853892.ch17

  3. A Short Guide to Clinical Pharmacokinetics.
    https://link.springer.com/book/10.1007/978-981-97-4283-7

  4. Best Paper Awards. (n.d.). Research excellence evaluation criteria.
    https://bestpaperawards.com/

Paula Abola | Pharmacology | Editorial Board Member

Published on by Best Paper Awards

Mrs. Paula Abola | Pharmacology | Editorial Board Member

PhD Student and Professor | University of Jamestown | Germany

Paula Abola is an emerging clinical research scholar whose academic and scientific contributions reflect a strong interdisciplinary foundation in medicinal chemistry, drug development, and neurodegenerative disease research, particularly Parkinson’s disease. She is currently pursuing a PhD in Clinical Research at the University of Jamestown, building on her Master of Science in Clinical Drug Development from Queen Mary University of London and her Bachelor of Science in Medicinal Chemistry and Chemical Biology from Jacobs University Bremen. Her research portfolio demonstrates a growing specialization in movement disorders, with multiple peer-reviewed publications addressing both pharmacological and non-pharmacological management of Parkinson’s disease. Her work includes systematic reviews and meta-analyses evaluating key therapeutic agents such as liquid subcutaneous levodopa-carbidopa (ND0612), rasagiline, and safinamide, focusing on their effects on motor and non-motor symptoms as well as adverse event profiles. Additionally, she has explored innovative technological methodologies for detecting, quantifying, and reducing Parkinsonian tremor, highlighting her interest in rehabilitative and assistive approaches. Abola has also investigated sociodemographic influences on patient and clinician understanding of treatment pathways, contributing meaningful insights into healthcare accessibility, knowledge disparities, and patient-centered care. Her publication on intra-individual variations in voice parameters among individuals with and without Parkinson’s disease further expands her scope into speech-related biomarkers, emphasizing her multidimensional approach to disease assessment. Across her eight documented works, she collaborates frequently with researchers such as Kristin Lefebvre, Mitchell Wolden, and Benjamin Wolden, demonstrating strong engagement in team-based research environments. Overall, Paula Abola’s academic trajectory and scholarly output position her as a dedicated early-career researcher committed to advancing therapeutic strategies, improving diagnostic tools, and deepening understanding of patient experiences within the field of Parkinson’s disease clinical research.

Profile: ORCID

Featured Publications

  1. Abola, P., Lefebvre, K., & Wolden, M. (2025). Influence of sociodemographic variables on patient and practitioner knowledge of pharmacological management options for Parkinson’s disease. American Journal of Medical and Clinical Research & Reviews, 2025.

  2. Abola, P., Lefebvre, K. (2025). Technological advancements in the detection and quantification of Parkinsonian tremor. Topics in Geriatric Rehabilitation, July 2025.

  3. Abola, P., Wolden, M. (2025). Intra-individual variations in voice variables among individuals with and without Parkinson’s disease. Cureus, March 29, 2025.

  4. Abola, P., Wolden, M., & Lefebvre, K. (2024). Liquid subcutaneous levodopa-carbidopa ND0612 effects on motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

  5. Abola, P., Wolden, M. (2024). Monoamine oxidase-B inhibitor rasagiline effects on motor and non-motor symptoms in individuals with Parkinson’s disease: A systematic review and meta-analysis. Advances in Parkinson’s Disease, 2024.

Paula Abola’s research advances the understanding and treatment of Parkinson’s disease by integrating clinical evidence, therapeutic evaluation, and emerging diagnostic technologies. Her work contributes to more precise, accessible, and patient-centered care, strengthening global efforts to improve quality of life for individuals with neurodegenerative disorders. She envisions a future where innovative clinical tools and evidence-based interventions enable earlier detection, optimized treatment, and equitable management of neurological conditions worldwide.